Epcoritamab is a novel bispecific IgG1k/lambda antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL).
Purity:
>99.0%
CAS Number:
[2134641-34-0]
Target:
CD20
* VAT and and shipping costs not included. Errors and price changes excepted